Sigmoid <i>E</i> <sub>max</sub> Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime
Philipp Knechtle, Stuart Shapiro, Ian Morrissey, Cyntia De Piano, Adam Belley
Abstract
The use of carbapenem antibiotics to treat infections caused by Enterobacterales expressing increasingly aggressive extended-spectrum β-lactamases (ESBLs) has contributed to the emergence of carbapenem resistance. Enmetazobactam is a novel ESBL inhibitor being developed in combination with cefepime as a carbapenem-sparing option for infections caused by ESBL-producing Enterobacterales .
Topics & Concepts
CefepimeSigmoid functionCarbapenemCheckerboardAntibioticsMedicineCephalosporinAntibacterial agentMicrobiologyKlebsiella pneumoniaeChromatographyMinimum inhibitory concentrationAntibacterial activityChemistryKlebsiellaBiologyAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyBacterial Identification and Susceptibility Testing